Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.
Lovenberg
T W
TW
Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill 27599.
Brewster
W K
WK
Mottola
D M
DM
Lee
R C
RC
Riggs
R M
RM
Nichols
D E
DE
Lewis
M H
MH
Mailman
R B
RB
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D010617:Phenanthridines / Q000494:pharmacology*; D051381:Rats; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D013134:Spiperone / Q000378:metabolism
D015259:Dopamine Agents; D010617:Phenanthridines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; C061532:dihydrexidine; D013134:Spiperone; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000262:Adenylyl Cyclases